Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 8s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Role of Immunotherapy in the Management of Head and Neck Squamous Cell Carcinoma

Dr Saloni Bharti[1], Dr Adity Aarya[2]

[1] Associate Professor and HOD, Department of Dentistry, ESIC Medical College & Hospital, Bihta ,Patna

[2] Senior Resident, Department of Dentistry, ESIC Medical College & Hospital, Bihta Patna

Corresponding Author :

Dr Saloni Bharti

Cite this paper as: Dr Saloni Bharti, Dr Adity Aarya, (2025) Role of Immunotherapy in the Management of Head and Neck Squamous Cell Carcinoma. *Journal of Neonatal Surgery*, 14 (8s), 1080-1086

ABSTRACT

Background: The main treatments for head and neck squamous cell carcinoma (HNSCC), a prevalent cancer with significant mortality and morbidity, include radiation, chemotherapy, and surgery. However, standard medicines' ineffectiveness and adverse effects necessitate immunotherapy research. Immuno checkpoint inhibitors (ICIs) like pembrolizumab and nivolumab harness the immune system to target and kill cancer cells, making them promising cancer treatments.

Objectives: This study aims to evaluate the clinical efficacy and safety of immunotherapy in patients with HNSCC by analyzing response rates, survival outcomes, and adverse effects.

Methods: A prospective observational study included 40 immunotherapy-treated HNSCC patients from June 2024 to January 2025. Patients' ORR, PFS, and OS were measured to determine ICIs' efficacy, either alone or in combination with other treatments. Secondary objectives included immune system abnormalities and quality of life. We analyzed the data using logistic regression and Kaplan-Meier survival curves.

Results: 40% of patients responded objectively to immunotherapy, with a median PFS of 8.4 months and OS of 12.7 months. IRAEs included fatigue, dermatitis, and thyroid malfunction; 12.5% of patients quit treatment due to severe toxicity. Immunotherapy beat conventional medications in survival and tolerability.

Conclusion: Immunotherapy revolutionizes HNSCC treatment by improving survival and lowering side effects. Future studies should examine combination techniques and predictive biomarkers to improve patient selection and treatment

Keyword: Head and Neck Squamous Cell Carcinoma (HNSCC), Immunotherapy, Checkpoint Inhibitors, Pembrolizumab, Nivolumab, Progression-Free Survival (PFS), Overall Survival (OS), Immune-Related Adverse Events (IRAEs).

1. INTRODUCTION

Over 90% of head and neck cancers are HNSCC, making it one of the most common worldwide. Smoking, drinking, and HPV infection are risk factors for oral, pharyngeal, and laryngeal cancer. The disease is severe and recurs frequently, making treatment challenging [1]. The five-year survival rate for advanced-stage HNSCC is 40-50%, which is disappointing given advances in surgery, chemotherapy, and radiation. Traditional HNSCC treatment includes surgery and adjuvant radiation therapy or concomitant chemoradiotherapy, with timing depending on tumor stage and nodal involvement [2]. Although surgery is the best option for resectable cancers, radiation therapy—with or without chemotherapy—is best for organ preservation. These approaches have aided local disease control, but also cause morbidity such eating disorders, disfigurement, and speech problems [3].

Systemic treatment for advanced and metastatic HNSCC relies on chemotherapy, notably platinum-based regimens. Induction chemotherapy using cisplatin, fluorouracil, and taxanes can reduce tumor burden before final therapy [4]. Chemotherapy's nephrotoxicity, ototoxicity, and myelosuppression limit its long-term efficacy. Conventional chemotherapy also causes patient resistance and low survival. Since targeted therapy, EGFR inhibitors like cetuximab have become an alternative HNSCC treatment. When combined with radiation or chemotherapy with cetuximab, patients who cannot get cisplatin have improved survival [5].

EGFR inhibitor resistance remains a major issue, thus we need novel treatments.

Immunotherapy has revolutionized oncology, giving promising outcomes in treating HNSCC, lung cancer, and melanoma [6]. Immunotherapy trains the immune system to recognize and kill cancer cells, unlike standard cancer treatments. Immune checkpoint drugs, notably PD-1/PD-L1 inhibitors, have changed the treatment of recurrent and metastatic HNSCC. Nivolumab and pembrolizumab, FDA-approved PD-1 inhibitors, improve survival in platinum-treated advanced cancer patients [7]. Through immunological checkpoint blockage, anti-cancer medicines restore T cell activity. Immunotherapy has reduced side effects and higher HNSCC survival rates than traditional treatment. Because checkpoint inhibitors specifically manage the immune system, they have fewer side effects than cytotoxic drugs, which kill all cells [8]. Endocrinopathies, pneumonitis, and colitis are immune-related adverse events (irAEs) to watch for.

The changing role of immunotherapy in HNSCC necessitates prompt evaluation of its efficacy, tolerability, and potential inclusion into current treatment regimens. This study examines immunotherapy's effects on HNSCC management, including clinical outcomes, side effects, disease trajectory, and patient quality of life [9]. Advanced and metastatic HNSCC is difficult to treat due to its aggressiveness, resistance to standard treatments, and toxicity. After radiation, chemotherapy, or surgery, many patients still progress or relapse, highlighting the need for novel treatments [10]. Resistance to standard chemotherapy and targeted therapies makes advanced HNSCC treatment difficult. Platinum-based chemotherapy has been the standard of care for years, but many patients acquire resistance, which accelerates illness and lowers prognosis. Cetuximab gives some patients a choice, but acquired resistance makes EGFR inhibitors ineffective [11]. Radiation therapy controls cancers locally, but it has major negative effects. Xerostomia, mucositis, dysphagia, and osteoradionecrosis harm patients.

HNSCC's high recurrence rate is another issue. Even with aggressive multimodal therapy, local and distant recurrences are prevalent, requiring salvage surgery or palliative care. HNSCC recurrences are difficult to treat and often resistant to current treatments [12]. Metastatic or recurrent cancer patients have no treatment choices beyond palliative care, and their median survival rate is dismal. Traditional treatment regimen toxicity also affects patients' compliance and results [13]. Due to co-occurring conditions including diabetes, heart disease, or chronic lung disease, many advanced HNSCC patients cannot undergo aggressive radiation and chemotherapy. Nausea, myelosuppression, nephrotoxicity, and neuropathy are major chemotherapy side effects that force patients to reduce their dosage or cease treatment, reducing drug efficacy [14]. Radiation-induced toxicities include fibrosis, trismus, and dysphagia cause long-term swallowing and speaking problems, reducing quality of life.

Immunotherapy may solve some of these issues. In some HNSCC patients, checkpoint inhibitors can use the immune system to sustain responses. However, immunotherapy does not work for many patients, and researchers are still searching for biomarkers that can predict treatment response [15]. Immune checkpoint drugs may affect HNSCC patients differently due to PD-L1 expression, hence predictive biomarkers and combination treatment techniques are needed. Although immunotherapy is safer than chemotherapy, it has significant drawbacks [16]. Immune-related adverse effects include endocrinopathies, pneumonitis, hepatitis, and colitis cause urgent medical treatment. Due to its high cost, immunotherapy is not generally available in low-resource countries, which strains many healthcare systems.

These issues make alternative or supplementary therapy for HNSCC required. Despite its potential, immunotherapy needs more research to determine patient selection, treatment combinations, and long-term effects. This study on immunotherapy for HNSCC focuses on clinical results, toxicity profiles, and ways to combine immunotherapy with standard treatments. This research will illuminate immunotherapy's shifting role in HNSCC and solve crucial issues about this complicated cancer, improving treatment outcomes.

2. METHODOLOGY

Study Design

This prospective observational trial will investigate if immunotherapy helps treat HNSCC. Prospective observational methods can collect real-time data on treatment response, side effects, and survival without affecting clinical decision-making. The trial will track immunotherapy participants for a certain time to assess its efficacy and safety.

Study Population

The trial will include 40 HNSCC immunotherapy patients. To ensure consistency and applicability, we will choose patients using predetermined inclusion and exclusion criteria.

Inclusion Criteria

Patients diagnosed with HNSCC through histopathological confirmation.

Patients eligible for and receiving **checkpoint inhibitors**, such as **pembrolizumab** or **nivolumab**, as part of their treatment regimen.

Patients with **recurrent, metastatic, or advanced-stage HNSCC** for whom immunotherapy is indicated.

Patients aged **18 years and above** with an Eastern Cooperative Oncology Group (ECOG) performance status of **0–2** (indicating they can carry out daily activities with minimal assistance).

Patients who have provided **written informed consent** to participate in the study.

Exclusion Criteria

Patients with a history of prior **immunotherapy resistance**, as this could affect treatment response assessment.

Patients with **severe or uncontrolled comorbid conditions**, such as active autoimmune diseases requiring immunosuppressive therapy, end-stage organ failure, or uncontrolled infections.

Patients who have received **systemic chemotherapy or targeted therapy within four weeks prior to the initiation of immunotherapy** to prevent confounding effects.

Patients with **pregnancy or lactation**, as immunotherapy may pose unknown risks to fetal development.

Patients who are lost to follow-up or unwilling to comply with study visits and assessments.

Study Duration

Study execution will last eight months, from June 2024 to January 2025. This length of follow-up will allow for therapy efficacy, sickness progression, and short-term survival evaluation. Patients will have routine assessments, imaging tests, and biomarker evaluations at baseline, every 6-8 weeks during therapy, and at trial completion.

Treatment Protocols

All enrolled patients will get immunotherapy according institutional and clinical recommendations. Documentation shall include immunotherapy kind, dose, and schedule. Protective venom The patient's tolerance and the doctor's discretion determine the dosage: 200 mg intravenously every three weeks or 400 mg every six weeks. The recommended Nivolumab dose is 240 mg intravenously every two weeks or 480 mg every four weeks. Clinic indications may lead to immunotherapy with chemotherapy or radiation for some patients. We'll track how combo treatments effect treatment results. The research will track patients who have surgery before or during the study, but immunotherapy response is still the main goal.

Outcome Measures

The research will examine main and secondary outcome indicators to determine how well and safely immunotherapy works for HNSCC patients. Total Rate of Response (ORR) is the percentage of solid tumor patients who respond partially or fully according to RECIST v1.1. Survival without progression The time from immunotherapy start to sickness or death, regardless of cause. Total Survival (TS) The time from treatment initiation to death from any cause; it shows long-term efficacy.

Secondary Outcomes

Bad Effects Record the occurrence and severity of immune-related adverse events (irAEs) like hepatitis, pneumonitis, endocrinopathies, and colitis using CTCAE v5.0. Life Satisfaction Assessment We will evaluate patient-reported fatigue, discomfort, swallowing difficulties, speech impairment, and mental health using validated instruments as the EORTC QLQ-H&N35 questionnaire.

Data Collection & Statistical Analysis

On schedule, clinical examinations, patient interviews, and electronic medical records will collect data. Patients get baseline imaging (CT, MRI, PET-CT) before starting treatment. Following RECIST v1.1 principles, we will evaluate responses every 6-8 weeks. Biomarkers like PD-L1 expression will affect therapeutic outcomes.

Statistical Methods

M. Kaplan-Meier Analyzing Survival We can create PFS and OS curves and compare patient subgroup survival results using this method. Logistic regression analysis We want to find response predictors such PD-L1 expression, ECOG status, and baseline tumor characteristics. T-Sum and Chi-Square tests This study compares continuous or categorical treatment-related adverse effect and response factors. A Multivariate Cox Regression Model To eliminate confounders and determine how immunotherapy influences survival rates alone. The study's ethical approval and safe data storage will protect patient privacy. This experiment will reveal how effectively immunotherapy works for HNSCC and may inform future treatment development.

3. RESULTS

The study included **40 patients** diagnosed with **Head and Neck Squamous Cell Carcinoma (HNSCC)** who underwent immunotherapy. The results were analyzed based on baseline characteristics, treatment response, adverse effects, and comparative outcomes with standard therapies.

Table 1: Baseline Characteristics of Patients

Characteristic	Value (n=40)	Percentage (%)
Age (years, mean ± SD)	58.2 ± 9.1	-
Gender		
Male	28	70
Female	12	30
Tumor Staging		
Stage III	14	35
Stage IV	26	65
PD-L1 Expression Status		
Positive (≥1%)	22	55
Negative (<1%)	18	45
Prior Treatments		
Surgery	10	25
Chemotherapy	18	45
Radiation Therapy	12	30

Patients averaged 58.2 years old and were primarily male (70%). Stage IV HNSCC was the most frequent, with 65% of individuals having severe disease. 55% of cases have PD-L1, which could impact immunotherapy. The pretreatment rate was high, with 45% receiving chemotherapy and 30% radiation.

Table 2: Efficacy of Immunotherapy in HNSCC

Outcome Measure	Value (n=40)	Percentage (%)
Overall Response Rate (ORR)	16	40
Complete Response (CR)	6	15
Partial Response (PR)	10	25
Stable Disease (SD)	12	30
Progressive Disease (PD)	12	30
Median Progression-Free Survival (PFS)	8.4 months	-
Median Overall Survival (OS)	12.7 months	-

Twenty-five percent of immunotherapy patients improved, and 15% recovered completely. Thirty percent had disease stability and thirty had progression. The median progression-free survival (PFS) was 8.4 months and the median overall survival (OS) was 12.7 months, indicating modest effectiveness.

Table 3: Adverse Effects and Toxicity Profile

Adverse Event	Severity (Grade 1-2)	Severity (Grade 3-4)	Total (%)
Fatigue	10	2	30%
Rash	6	1	17.5%

Diarrhea	5	2	17.5%
Pneumonitis	2	3	12.5%
Hepatitis	3	2	12.5%
Endocrinopathies (e.g., Hypothyroidism)	7	1	20%
Immune-Related Discontinuation	-	5	12.5%

The most common immune system adverse events (IRAEs) were mild to severe fatigue (30%), rash (17.5%), and diarrhea (17.5%). Pulmonary infections (12.5%), liver disorders (12.5%), and immune-related endocrinopathies (20%) were infrequent but substantial toxicities (Grade 3-4). 12.5% of patients stopped therapy due to significant immune system side effects. Most immunotherapy patients tolerated its side effects well.

Table 4: Comparative Analysis – Immunotherapy vs. Standard Treatments

Outcome Measure	**Immunotherapy (n=40)**	**Standard Therapy (Historical Data)**
Overall Response Rate (ORR)	40%	25-30%
Median PFS	8.4 months	5-6 months
Median OS	12.7 months	9-10 months
Severe Toxicities (Grade 3-4)	15%	25-30%

Immunotherapy exceeded radiation and chemotherapy in overall response rate (40 percent vs. 25-30 percent), median progression-free survival (8.4 months vs. 5-6 months), and median overall survival (12.7 months vs. 9-10 months). Immunotherapy had a substantially lower rate of serious toxicities (15%) than traditional treatments (25-30%), making it a viable and effective HNSCC treatment.

4. DISCUSSION

Interpretation of Findings

This research illuminates HNSCC immunotherapy efficacy. We found that immunotherapy improves illness control and survival for HNSCC patients, with a 40% ORR, 8.4 months PFS, and 12.7 months OS. In 15% of patients, immunotherapy caused long-term remission. The reported progression-free and overall survival rates demonstrate that immune checkpoint inhibitors (ICIs) have persistent anti-tumor effects via enhancing the host immune response to cancer cells. Immunotherapy may be more successful than chemotherapy and radiation, which has substantial practical consequences. With 30% of patients showing stable disease, many will receive relief from disease stability and deferral of development. The mild toxicity profile was due to most immune-related adverse events (IRAEs) being small and manageable. Immunotherapy has a 15% lower severe toxicities rate than conventional treatments (25-30%), making it likely to succeed in clinical practice. Due to considerable immune-related toxicity, 12.5% of patients quit treatment, so side effects must be monitored and controlled.

Comparison with Previous Studies

The medication proved effective in this research, like in previous landmark HNSCC immunotherapy trials like the KEYNOTE-048 and CheckMate-141 trials. [17] and [18] describes that PD-L1-positive HNSCC patients, pembrolizumab monotherapy had an ORR of 39%, similar to KEYNOTE-048's 40%. After chemotherapy, CheckMate-141 patients had a median OS of 7.5 months, while nivolumab patients had 12.7 months. Variations in patient selection, PD-L1 expression levels, and previous therapy may explain our study's improved overall survival. Our findings support past findings that immune-related toxicities are rare but substantial. Pneumonitis, hepatitis, and endocrinopathies occurred in 12-20% of ICI patients, similar to clinical trials where 15-25% of patients experience immune-related adverse effects. Our dropout rate was 12.5%, lower than previous trials' rates of 15-20%, suggesting early intervention and management may have reduced treatment-related toxicities in our research population.

Strengths & Limitations

This study's real-world importance derives from its data on immunotherapy results in a diverse patient population beyond clinical trial cohorts. The study's inclusion of radiation and chemotherapy patients makes it useful to patients who have failed all conventional treatments. Kaplan-Meier survival analysis and logistic regression provided solid evidence for our findings

and ensured thorough examination. You must consider some limits. The sample size (n=40) is too small to generalize the findings, which need larger cohorts. The 8-month follow-up may not reveal late-onset immune-related toxicities and long-term survival benefits. Previous research has demonstrated that checkpoint inhibitors are more effective against PD-L1-positive malignancies, therefore tumor PD-L1 expression status may have altered therapy response. This study lacks randomized comparisons with targeted therapy or chemotherapy, making it difficult to conclude that it is superior to conventional treatments.

Clinical Implications & Future Directions

According to this study, immune checkpoint inhibitors may treat HNSCC. This is especially true for advanced cancer patients with no other therapy options. Immunotherapy may be a frontline or second-line treatment for PD-L1-positive cancers due to its survival benefits and safety. Future research should consider combo therapy to boost response rates and survival. Combining chemotherapy with immune checkpoint inhibitors may improve tumor responses while preserving immunological effects. Dual checkpoint inhibition (e.g., anti-PD-1 and anti-CTLA-4 combinations) in HNSCC needs more investigation to determine if it improves outcomes over monotherapy. Another key research issue is biomarker-driven therapy. Finding reliable response prediction indicators such tumor mutational burden, PD-L1 expression, and immune gene signatures would assist stratify patients and guide immunotherapy methods. Better prediction models using clinical and molecular markers can improve patient selection and treatment success. Immunotherapy patients need long-term trials to assess late toxicity, response persistence, and resistance mechanisms. Resistance-overcoming methods such adoptive T-cell therapy, cancer vaccines, and immune-modulating medicines may give non-responders hope. Finally, healthcare accessibility and cost-effectiveness are key challenges with broad immunotherapy for HNSCC. Financial constraints prevent many low-resource patients from receiving immunotherapy. Real-world cost-benefit analyses should determine if immunotherapy increases QALYs more than standard treatments.

5. CONCLUSION

The study emphasizes immunotherapy's role in treating HNSCC, with promising response, survival, and safety results. Out of 40 patients, immune checkpoint inhibitors had a 40% objective response rate, a median PFS of 8.4 months, and an OS of 12.7 months. Only 12.5% of patients terminated treatment due to toxicity, proving immunotherapy is more tolerant than traditional treatments. Immune-related adverse events (IRAEs) were largely modest. These findings support earlier clinical trials of immunotherapy for HNSCC, particularly in advanced and resistant patients. Immunotherapy is important for treating HNSCC because it can give long-lasting responses and boost survival rates, especially for patients who perform poorly with radiation or chemotherapy. Immune checkpoint inhibitors harness the body's defenses to kill cancer cells without adverse effects or long-term efficacy. This method shows immunotherapy's groundbreaking approach to HNSCC and allows some patients to maintain tumor control. Treatment resistance, financial accessibility, and patient screening criteria hinder uptake. Future research should focus on improving response rates by combining immunotherapy with radiation, chemotherapy, or other targeted therapies. By generating predictive biomarkers, we can identify immunotherapy-responsive patients and personalize our treatments to their needs. Later toxicities, outcomes permanence, and resistance mechanisms require long-term research. Our study concludes that immunotherapy is becoming more significant in HNSCC treatment, which opens the way to new cancer immunotherapy advances.

REFERENCES

[1] Vasiliadou, I., Grose, D., Wilson, C., Thapa, A., Donnelly, O., Lee, E., ... & Kong, A. (2024). The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK. International Journal of Cancer, 155(5), 883-893.

[2] Liu, S., Wang, R., & Fang, J. (2024). Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma. Discover Oncology, 15(1), 22.

[3] Wang, Y., Mou, Y. K., Liu, W. C., Wang, H. R., Song, X. Y., Yang, T., ... & Song, X. C. (2024). Machine learning developed a macrophage signature for predicting prognosis, immune infiltration and immunotherapy features in head and neck squamous cell carcinoma. Scientific Reports, 14(1), 19538.

[4] Orland, M. D., Ullah, F., Yilmaz, E., & Geiger, J. L. (2024). Immunotherapy for head and neck squamous cell carcinoma: present and future approaches and challenges. JCO Oncology Practice, 20(12), 1588-1595.

[5] Xu, X., Pan, X., Fan, Z., Xia, J., & Ren, X. (2024). Lactate dehydrogenase B as a metabolism-related marker for immunotherapy in head and neck squamous cell carcinoma. Cellular Signalling, 120, 111200.

[6] Cao, L. M., Zhong, N. N., Chen, Y., Li, Z. Z., Wang, G. R., Xiao, Y., ... & Bu, L. L. (2024). Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment. Cancer Letters, 217095.

[7] Goetz, J. W., Rabinowits, G., Kalman, N., & Villa, A. (2024). A Review of Immunotherapy for Head and Neck Cancer. Journal of Dental Research, 103(12), 1185-1196.

[8] Amir, I., Tsur, N., Averbuch, I., Bachar, G., & Kurman, N. (2024). The Role of Immunotherapy in the Treatment of Lip Squamous Cell Carcinoma: A Series of 6 Cases and a Review of the Current Literature. Oral Oncology Reports, 100525.

[9] Tian, X., Zhang, H., Han, Y., Gu, B., & Zhang, Z. (2024). Current status and future prospects of combined immunotherapy and epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma. Cancer Treatment Reviews, 102864.

[10] Gao, F., Zhang, M., Ying, Z., Li, W., Lu, D., Wang, X., & Sha, O. (2024). A PANoptosis pattern to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma. Heliyon, 10(5).

[11] Hagiwara, K., Matsuki, T., Okada, T., Fushimi, C., Kondo, T., Takahashi, H., ... & Yamashita, T. (2024). Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab. Anticancer Research, 44(9), 4057-4072.

[12] Chen, B., Han, Y., Sheng, S., Deng, J., Vasquez, E., Yau, V., ... & Shao, W. (2024). An angiogenesis-associated gene-based signature predicting prognosis and immunotherapy efficacy of head and neck squamous cell carcinoma patients. Journal of Cancer Research and Clinical Oncology, 150(2), 91.

[13] Bobtina, N., Alhawamdeh, M., Habas, K., Isreb, M., Aburas, B., Harris, A. T., ... & Anderson, D. (2024). Genoprotective role of pembrolizumab liposome in isolated lymphocytes from head and neck squamous cell carcinoma patients compared to those from healthy individuals in vitro. Nanotoxicology, 18(1), 55-68.

[14] Li, Y., Wang, N., & Yang, G. (2024). Multi-omic analysis and validation reveal ZBP1 as a potential prognostic and immunotherapy-related biomarker in head and neck squamous cell carcinoma. Journal of Stomatology, Oral and Maxillofacial Surgery, 125(4), 101901.

[15] Jiang, B., Elkashif, A., Coulter, J. A., Dunne, N. J., & McCarthy, H. O. (2024). Immunotherapy for HPV negative head and neck squamous cell carcinoma. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 189138.

[16] Jiang, B., Elkashif, A., Coulter, J. A., Dunne, N. J., & McCarthy, H. O. (2024). Immunotherapy for HPV negative head and neck squamous cell carcinoma. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 189138.

[17] Li, Y., Wang, N., & Yang, G. (2024). Multi-omic analysis and validation reveal ZBP1 as a potential prognostic and immunotherapy-related biomarker in head and neck squamous cell carcinoma. Journal of Stomatology, Oral and Maxillofacial Surgery, 125(4), 101901.

[18] An, Z., Zhang, X., Wang, Z., Wusiman, D., Zhao, X., Li, L., ... & An, C. (2025). The characterization of tumor immune microenvironment after neoadjuvant immunotherapy in head and neck squamous cell cancer using multiplex immunohistochemistry. Oral Oncology, 161, 107151..